Shares of infant formula maker Bubs Australia Ltd. soared the most in more than five years after the Sydney-based company struck a deal to ship its product to the U.S. to ease a severe shortage.
The stock surged as much as 77% in Sydney on Monday after the Food and Drug Administration said the company would provide the U.S. with at least 1.25 million cans of formula. President Joe Biden had earlier tweeted the news over the weekend, citing the equivalent volume in bottles.
I’ve got more good news: 27.5 million bottles of safe infant formula manufactured by Bubs Australia are coming to the United States.
— President Biden (@POTUS) May 27, 2022
We’re doing everything in our power to get more formula on shelves as soon as possible.
I’ve got more good news: 27.5 million bottles of safe infant formula manufactured by Bubs Australia are coming to the United States.
We’re doing everything in our power to get more formula on shelves as soon as possible.
The president’s tweet “should be helpful for the company’s marketing efforts, help position the brand as a safe and reliable foreign IMF manufacturer, and should be indirectly positive for sales of toddler formula,” Citigroup Inc. analysts said in a note Monday.
New Zealand formula maker A2 Milk Co. also benefited from the news, jumping as much as 13% in Wellington.
U.S. regulators have been taking steps to increase formula supplies as a shortage leaves shelves empty across the country. Bubs Australia, which has a market value of about A$420 million ($301 million), said it was working closely with the U.S. to determine how to deliver the products as quickly as possible, according to a statement.
More must-read stories from UnHerd
Hepatitis A outbreak linked to organic strawberries is being probed by the FDA
Eurovision winners sell trophy to crypto exchange for $900,000 to buy drones for Ukraine
Sign up for the UnHerd Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.